[ad_1]
Researchers from the US National Institute of Allergy and Infectious Diseases (NIAID), which developed the vaccine together with Moderna, studied the immune response of 34 vaccinated adults.
In an article in the New England Journal of Medicine, they said that antibodies to SARS-CoV-2 that prevent coronavirus from invading human cells “decreased over time as expected, but in all participants’ bodies for 3 months. its levels remained elevated after vaccination. “
The mRNA-1273 vaccine is given in two doses with a 4-week break.
Although the level of antibodies in test organisms has decreased over time, this is not necessarily a cause for concern.
Moderna is the company that developed the COVID-19 vaccine
© EPA – ELTA
NIAID Director Anthony Fauci and other experts have repeatedly argued that the immune system should remember the coronavirus later and produce new antibodies.
The study also showed that the Moderna vaccine activates certain immune cells, which help the body to ‘remember’ the coronavirus and fight it more easily in the future.
“This study provides evidence that a relatively strong antibody response persists 90 days after the second dose of the vaccine. The amount of antibodies produced by the vaccine was higher in younger patients than in older patients, but an immune response was observed. strong enough in patients up to age 70, ”said Benjamin Neuman, a virologist at the University of Texas.
The Moderna vaccine will be evaluated by the US Food and Drug Administration (FDA) on December 17. Patients may be allowed to administer the vaccine shortly after evaluation.
No part of this publication may be reproduced without the written permission of ELTA.
[ad_2]
